ROsuvastatin LOading and Clinical Outcomes Trial

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01936805

Acronym

ROLOCO

Enrollment

299

Registered

2013-09-06

Start date

2008-01-31

Completion date

2012-01-31

Last updated

2013-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis

Brief summary

The aim of the present study was to evaluate the effect of pre-procedural single high loading dose (40 mg) of rosuvastatin on the primary end-points of all cause mortality and composite of death or myocardial infarction from cardiovascular (CV) causes, target vessel revascularization (TVR), or stroke.

Interventions

DRUGRosuvastatin

A 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* statin-naive patients * stable ischemic heart disease * de novo lesions appropriate for PCI

Exclusion criteria

* current statin use * statin allergic patients * acute coronary syndromes * lesions not appropriate for PCI * refusal for participation * statin quitting during follow- up

Design outcomes

Primary

Measure	Time frame
all cause death and composite of death or myocardial infarction from CV causes, TVR, or stroke	4 year

Secondary

Measure	Time frame
all cause death	4 year
composite of death or myocardial infarction from CV causes, TVR, or stroke	4 year

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026